| Ytd | 73.82% | |
| 1y | 37.02% |
| Open | 10.36 | Prev Close | 10.55 | Low | 10.23 | High | 10.42 | Mkt Cap | 639.61M |
| Vol | 212.38K | Avg Vol | 1.21M | EPS | -1.26 | P/E | N/A | Forward P/E | -1.40 |
| Beta | 3.37 | Short Ratio | 1.37 | Inst. Own | 66.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 8.29 | 200-d Avg | 6.76 | 1yr Est | 29.14 |
SGMT News
Shares of Sagimet Biosciences Inc. (NASDAQ: SGMT - Get Free Report) have been given a consensus rati
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with
All clinical trial sites identified and CRO retainedPatient screening expected to begin in October 2
All clinical trial sites identified and CRO retained Patient screening expected to begin in October
FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl
Sagimet Biosciences NASDAQ: SGMT plans to begin a Phase III study of its oral fatty acid synthase, o
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outp
Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to in
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.26) per share which missed the an
FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin
SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin
US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.
After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc.
https://www.gov.uk/government/news/resmetirom-rezdiffra-authorised-to-treat-metabolic-dysfunction-as
Phase 1 clinical data poster selected as a Best of EASL 2026 presentationCombination of denifanstat
Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outp
Sagimet Biosciences receives a Buy rating, driven by denifanstat's potential in MASH and acne, despi
SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clini
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.33) per share which beat the anal
Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifa
Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3
Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investor
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lo
Sagimet Biosciences Inc. (NASDAQ:SGMT) shares are surging on Monday, up 44% as the company announced
Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with
The biopharma company confirmed it's still aiming at the United States' acne-treatment market.
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to in
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.29) per share which beat the anal
Guggenheim analyst Seamus Fernandez initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable
Barclays analyst Eliana Merle initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Equa
License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom activ
